Prosensa, GSK announce primary endpoint not met in drisapersen Phase III study

theflyonthewall.com

GlaxoSmithKline (GSK) and Prosensa (RNA) announced that GSK's Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy patients with an amenable mutation, did not meet the primary endpoint of a statistically significant improvement in the 6 Minute Walking Distance test compared to placebo. Full evaluation of the benefit-to-risk profile of drisapersen treatment across all studies is anticipated to be completed by year end. This may include analyses of pooled results from various drisapersen studies.

Rates

View Comments (0)